Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis Dahkki Taisuke Ito, Kazuo Tsuchiya, Rie Mori, Takuro Akashi, Yoshiyuki Oyama, Masaki Ikeda

Fáttát: “…Osimertinib…”
Viečča ollesdeavstta

Severe stomatitis caused by osimertinib combined with gefitinib: A case report Dahkki Ya‐ning Zhu, Li Li, Peng Zhang, Yan Zuo, Yu Lei, Jun Bai, Lu Cao, Zhen‐Jun Guo

Fáttát: Viečča ollesdeavstta

PD‐L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR‐mutant non‐small cell lung cancer cells Dahkki Dantong Sun, Puyuan Xing, Junling Li

Fáttát: Viečča ollesdeavstta

Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib Dahkki Sun Min Lim, MD, PhD, San-Duk Yang, PhD, Sangbin Lim, PhD, Hyo Sup Shim, MD, PhD, Byoung Chul Cho, MD, PhD

Fáttát: Viečča ollesdeavstta

EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report Dahkki Xinyu von Buttlar, MD, MS, Joshua E. Reuss, MD, Stephen V. Liu, MD, Chul Kim, MD, MPH

Fáttát: Viečča ollesdeavstta

Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma Dahkki June Hong Ahn

Fáttát: Viečča ollesdeavstta

Research Progress of Osimertinib Supported by Nanodrug Delivery System Against Non-small Cell Lung Cancer Dahkki LIU Rugui, ZHAO Ruirui, LIU Chunzhao, WU Xiao

Fáttát: Viečča ollesdeavstta

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs Dahkki Hsu-Yuan Chen, Chia-Hung Chen, Wei-Chih Liao, Yu-Chao Lin, Hung-Jen Chen, Te-Chun Hsia, Wen-Chien Cheng, Chih-Yen Tu

Fáttát: Viečča ollesdeavstta

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib Dahkki Kejing Tang, Neng Jiang, Yukun Kuang, Qiong He, Shuhua Li, Jiping Luo, Wenting Jiang, Yangshan Chen, Yu Sun, Lili Chen, Yanyang Chen, Junfeng Zhu, Yongmei Cui, Han Wan, Zunfu Ke

Fáttát: Viečča ollesdeavstta

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis Dahkki Jie Wang, MD, PhD, Yi-Long Wu, MD, Shun Lu, MD, PhD, Qun Wang, MD, Shanqing Li, MD, Wen-Zhao Zhong, MD, PhD, Qiming Wang, MD, Wei Li, MD, PhD, Buhai Wang, MD, Jun Chen, MD, Ying Cheng, MD, Hongbing Duan, MD, Gaofeng Li, MD, Li Shan, MD, Yangbo Liu, MS, Jing Liu, MD, Xiangning Huang, PhD, Ana Bolanos, MD, Jie He, MD, PhD

Fáttát: Viečča ollesdeavstta

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A R... Dahkki Xue Yang, Yang Xia, Liyan Xu, Li Liang, Minglei Zhuo, Meina Wu, Tongtong An, Ziping Wang, Yuyan Wang, Jianjie Li, Jia Zhong, Hanxiao Chen, Bo Jia, Jingjing Wang, Jun Zhao

Fáttát: “…osimertinib…”
Viečča ollesdeavstta

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases Dahkki Mei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, Hao Sun, Kai Yin, Ben-Yuan Jiang, Jin-Ji Yang, Xu-Chao Zhang, Qing Zhou, Chong-Rui Xu, Zhen Wang, Hua-Jun Chen, De-Xiang Zhou, Yi-Long Wu

Fáttát: Viečča ollesdeavstta

Leukocytes telomere length as a biomarker of adverse drug reactions induced by Osimertinib in advanced non-small cell lung cancer Dahkki Narumol Trachu, Thanyanan Reungwetwattana, Jennis Meanwatthana, Chonlaphat Sukasem, Teerapat Majam, Wacharapol Saengsiwaritt, Jiraphun Jittikoon, Wanvisa Udomsinprasert

Fáttát: Viečča ollesdeavstta

Fam-Trastuzumab-Deruxtecan and Osimertinib Combination to Target HER2 Driven Resistance in a Patient With NSCLC After Osimertinib Progression: Case Report Dahkki Hailey M. Hirata, PharmD, Carrie B. Lee, MD, MPH, Kevin Y. Chen, PharmD, MS

Fáttát: “…Osimertinib…”
Viečča ollesdeavstta

Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA? Dahkki Arter ZL, Nagasaka M

Fáttát: Viečča ollesdeavstta

Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon EGFR Mutations Dahkki Christoforos Astaras, Adrienne Bettini, Daniel C. Betticher

Fáttát: Viečča ollesdeavstta

Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment Dahkki Leydis Luna Torres, Neyder Contreras Puentes, Antistio Avíz Amador

Fáttát: Viečča ollesdeavstta

Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report Dahkki Hongming Wang, Zhijun Wu, Yangfeng Du, Tao Wu, Wei Tian, Wen Dong, Juan Cai, Jiang Zheng, Yan Zhang, Shiyan Li, Wei Xu, Jing Qin, Zemin Xiao

Fáttát: “…osimertinib…”
Viečča ollesdeavstta

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report Dahkki Fionnuala Crowley, MB BCh BAO, Bailey G. Fitzgerald, MD, Aarti S. Bhardwaj, MD, Irine Siraj, MD, Cardinale Smith, MD, PhD

Fáttát: “…Osimertinib…”
Viečča ollesdeavstta

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction Dahkki Rui Han, Shuai Hao, Conghua Lu, Chong Zhang, Caiyu Lin, Li Li, Yubo Wang, Chen Hu, Yong He

Fáttát: Viečča ollesdeavstta